Beth E. Dunning - Concepedia

Author

Beth E. Dunning

Also Known As

B E Dunning, B. Dunning, B. E. DUNNING, B. E. Dunning, B.E. Dunning, BETH E. DUNNING, BETH ELAINE DUNNING, Beth Dunning, Beth E Dunning, Beth E. Dunning

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Lund University University of Washington Medical Center Novartis (Switzerland)University of Washington

About

Beth E. Dunning is an author at Novartis (United States) specializing in medicine, physiology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	26	2.3K
2	Health Sciences	6	6	184
3	Natural Sciences	2	2	729
4	Education	1	1	178
5	Public Health	1	1	86

Beth E. Dunning

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(<i>S</i>)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties Edwin B. Villhauer, J. A. Brinkman, Goli B. Naderi, Journal of Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryPharmaceutical ScienceSelective Dpp-iv InhibitorBiochemistry	2003	609
Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes Andrea Mari, William M. Sallas, Yanling He, The Journal of Clinical Endocrinology & Metabolism	2005	361
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Niina Matikainen, S. Mänttäri, Anja Schweizer, Diabetologia Metabolic SyndromeCardiovascular DiseaseDiabetesPharmacologyType 2	2006	334
The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients Bogdan Balas, Muhammad R. Baig, Catherine E. Watson, The Journal of Clinical Endocrinology & Metabolism	2007	242
Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes Adrian Vella, Gerlies Bock, Paula D. Giesler, Diabetes	2007	200
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes Bo Åhrén, Anja Schweizer, S. Dejager, The Journal of Clinical Endocrinology & Metabolism	2009	182
Galanin: a novel pancreatic neuropeptide Beth E. Dunning, Bo Åhrén, Richard C. Veith, American Journal of Physiology-Endocrinology and Metabolism Synthetic Porcine GalaninSynthetic GalaninImmunologyEducationNovel Pancreatic Neuropeptide	1986	178
Importance of Early Insulin Secretion Priscilla Hollander, Sherwyn Schwartz, Marjorie Gatlin, Diabetes Care	2001	129
1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(<i>S</i>)-pyrrolidinecarbonitrile: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties Edwin B. Villhauer, J. A. Brinkman, Goli B. Naderi, Journal of Medicinal Chemistry Pharmaceutical SciencePeptide SciencePharmacotherapyPharmaceutical ChemistryMolecular Pharmacology	2002	120
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2‐year treatment of patients with type 2 diabetes and mild hyperglycaemia* Werner A. Scherbaum, Anja Schweizer, Andrea Mari, Diabetes Obesity and Metabolism	2008	115

Page 1